RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Catalyst Biosciences Stock

Catalyst Biosciences Net Income 2024

Catalyst Biosciences Net Income

-1.16 M USD

Ticker

CBIO

ISIN

US14888D2080

WKN

A2DLUK

In 2024, Catalyst Biosciences's profit amounted to -1.16 M USD, a -81.25% increase from the -6.2 M USD profit recorded in the previous year.

The Catalyst Biosciences Net Income history

YEARNET INCOME (undefined USD)
2028e-
2027e-
2026e-29.24
2025e-0.77
2024e-1.16
2023e-6.2
2022-8.24
2021-87.93
2020-56.24
2019-55.18
2018-30.06
2017-25.51
2016-16.95
2015-14.76
2014-6.61
2013-9.97
2012-7
2011-8.53
201010.9
2009-39.4
2008-25.66
2007-28.07
2006-1.24
2005-40.23
2004-43.08
2003-27.74

Catalyst Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Catalyst Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Catalyst Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Catalyst Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Catalyst Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Catalyst Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Catalyst Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Catalyst Biosciences’s growth potential.

Catalyst Biosciences Revenue, EBIT and net profit per share

DateCatalyst Biosciences RevenueCatalyst Biosciences EBITCatalyst Biosciences Net Income
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined-83,640 undefined-29.24 M undefined
2025e0 undefined-692,580 undefined-774,588.05 undefined
2024e0 undefined-1.26 M undefined-1.16 M undefined
2023e0 undefined-6.28 M undefined-6.2 M undefined
2022794,000 undefined-29.41 M undefined-8.24 M undefined
20217.34 M undefined-87.89 M undefined-87.93 M undefined
202020.95 M undefined-56.57 M undefined-56.24 M undefined
20190 undefined-57.28 M undefined-55.18 M undefined
201810,000 undefined-33.82 M undefined-30.06 M undefined
20171.02 M undefined-21.82 M undefined-25.51 M undefined
2016400,000 undefined-20.42 M undefined-16.95 M undefined
20151.75 M undefined-13.8 M undefined-14.76 M undefined
20141.81 M undefined-7.51 M undefined-6.61 M undefined
2013520,000 undefined-10.12 M undefined-9.97 M undefined
201257.86 M undefined-4.42 M undefined-7 M undefined
201197.64 M undefined-9.75 M undefined-8.53 M undefined
201085.71 M undefined13.12 M undefined10.9 M undefined
200925.06 M undefined-40.33 M undefined-39.4 M undefined
200820.09 M undefined-28.14 M undefined-25.66 M undefined
200711.58 M undefined-31.77 M undefined-28.07 M undefined
200627.54 M undefined-400,000 undefined-1.24 M undefined
20051.18 M undefined-29.94 M undefined-40.23 M undefined
20043.74 M undefined-24.39 M undefined-43.08 M undefined
20032.46 M undefined-20.06 M undefined-27.74 M undefined

Catalyst Biosciences stock margins

The Catalyst Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Catalyst Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Catalyst Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Catalyst Biosciences's sales revenue. A higher gross margin percentage indicates that the Catalyst Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Catalyst Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Catalyst Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Catalyst Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Catalyst Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Catalyst Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Catalyst Biosciences Margin History

Catalyst Biosciences Gross marginCatalyst Biosciences Profit marginCatalyst Biosciences EBIT marginCatalyst Biosciences Profit margin
2028e-0.5 %0 %0 %
2027e-0.5 %0 %0 %
2026e-0.5 %0 %0 %
2025e-0.5 %0 %0 %
2024e-0.5 %0 %0 %
2023e-0.5 %0 %0 %
2022-0.5 %-3,703.65 %-1,038.04 %
2021-0.57 %-1,197.79 %-1,198.32 %
202056.26 %-270.05 %-268.48 %
2019-0.5 %0 %0 %
2018-0.5 %-338,200 %-300,600 %
2017-0.5 %-2,139.22 %-2,500.98 %
2016-0.5 %-5,105 %-4,237.5 %
2015-0.5 %-788.57 %-843.43 %
2014-0.5 %-414.92 %-365.19 %
2013-0.5 %-1,946.15 %-1,917.31 %
2012-0.5 %-7.64 %-12.1 %
2011100 %-9.99 %-8.74 %
2010100 %15.31 %12.72 %
200997.25 %-160.93 %-157.22 %
200896.27 %-140.07 %-127.73 %
200793.78 %-274.35 %-242.4 %
200698.33 %-1.45 %-4.5 %
200559.32 %-2,537.29 %-3,409.32 %
200494.65 %-652.14 %-1,151.87 %
200369.92 %-815.45 %-1,127.64 %

Catalyst Biosciences Aktienanalyse

What does Catalyst Biosciences do?

Catalyst Biosciences Inc. is a biotechnology company specializing in the development of innovative therapies for rare diseases and severe bleeding disorders. They collaborate with doctors, academics, and patient organizations to bring new treatment options to the market. Their business model is based on the development of proteins that influence the blood clotting process to prevent or reduce bleeding. They use a proprietary technology called Protease Engineering Platform (PEP) to make customized proteins. Catalyst Biosciences Inc. focuses on therapies for rare diseases such as hemophilia A and B, hemorrhagic diathesis, and other rare diseases like factor XIII deficiency or thrombasthenia. They offer a range of products, including CB 2679d, CB 813d, and CB 2679f for the treatment of hemophilia B. Catalyst Biosciences Inc. has achieved milestones and is considered one of the most promising companies in the industry. With its innovative technology and comprehensive portfolio, it has the potential for further success. Catalyst Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Catalyst Biosciences's Profit Margins

The profit margins of Catalyst Biosciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Catalyst Biosciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Catalyst Biosciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Catalyst Biosciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Catalyst Biosciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Catalyst Biosciences stock

How much profit has Catalyst Biosciences made this year?

Catalyst Biosciences has made -1.16 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -81.25% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Catalyst Biosciences publish its earnings?

Catalyst Biosciences publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Catalyst Biosciences?

The profits of Catalyst Biosciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Catalyst Biosciences?

You can learn more about the earnings of Catalyst Biosciences by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Catalyst Biosciences pay?

Over the past 12 months, Catalyst Biosciences paid a dividend of 1.43 USD . This corresponds to a dividend yield of about 8.01 %. For the coming 12 months, Catalyst Biosciences is expected to pay a dividend of 0.24 USD.

What is the dividend yield of Catalyst Biosciences?

The current dividend yield of Catalyst Biosciences is 8.01 %.

When does Catalyst Biosciences pay dividends?

Catalyst Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Catalyst Biosciences?

Catalyst Biosciences paid dividends every year for the past 0 years.

What is the dividend of Catalyst Biosciences?

For the upcoming 12 months, dividends amounting to 0.24 USD are expected. This corresponds to a dividend yield of 1.34 %.

In which sector is Catalyst Biosciences located?

Catalyst Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Catalyst Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Catalyst Biosciences from 1/12/2023 amounting to 0.24 USD, you needed to have the stock in your portfolio before the ex-date on 1/13/2023.

When did Catalyst Biosciences pay the last dividend?

The last dividend was paid out on 1/12/2023.

What was the dividend of Catalyst Biosciences in the year 2023?

In the year 2023, Catalyst Biosciences distributed 1.43 USD as dividends.

In which currency does Catalyst Biosciences pay out the dividend?

The dividends of Catalyst Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Catalyst Biosciences

Our stock analysis for Catalyst Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Catalyst Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.